Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood.
ELISA
PD-1
PD-L1
PD-L2
biomarker
preanalytical validation
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
11 Oct 2022
11 Oct 2022
Historique:
received:
14
07
2022
revised:
30
09
2022
accepted:
03
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
The interaction between programmed death-1 receptor PD-1 and its ligands PD-L1 and PD-L2 is involved in self-tolerance, immune escape of cancer, cardiovascular diseases, and COVID-19. As blood-based protein markers they bear great potential to improve oncoimmunology research and monitoring of anti-cancer immunotherapy. A variety of preanalytical conditions were tested to assure high quality plasma sample measurements: (i) different time intervals and storage temperatures before and after blood centrifugation; (ii) fresh samples and repeated freeze-thaw-cycles; (iii) different conditions of sample preparation before measurement. Concerning short-term stability, acceptable recoveries for PD-1 between 80 and 120% were obtained when samples were kept up to 24 h at 4 and 25 °C before and after blood centrifugation. Similarly, recoveries for PD-L2 were acceptable for 24 h at 4 °C and 6 h at 25 °C before blood centrifugation and up to 24 h at 4 and 25 °C after centrifugation. Variations for PD-L1 were somewhat higher, however, at very low signal levels. Sample concentrations (ng/mL) were neither affected by the freezing process nor by repeated freeze-thaw cycles with coefficients of variation for PD-1: 9.1%, PD-L1 6.8%, and PD-L2 4.8%. All three biomarkers showed good stability regarding preanalytic conditions of sample handling enabling reliable and reproducible quantification in oncoimmunology research and clinical settings of anti-cancer immunotherapy.
Identifiants
pubmed: 36289796
pii: biomedicines10102534
doi: 10.3390/biomedicines10102534
pmc: PMC9598997
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Anticancer Res. 2012 May;32(5):2075-8
pubmed: 22593491
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Immunity. 2016 May 17;44(5):955-72
pubmed: 27192563
JNCI Cancer Spectr. 2021 Jan 27;5(3):
pubmed: 34084999
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279
pubmed: 30393621
Biomark Res. 2020 Aug 26;8:34
pubmed: 32864131
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35131863
Biochem Med (Zagreb). 2013;23(1):70-7
pubmed: 23457767
Clin Chem. 2015 Jun;61(6):809-20
pubmed: 25882892
Cancer Cell. 2015 Apr 13;27(4):439-49
pubmed: 25858803
Front Med. 2019 Feb;13(1):32-44
pubmed: 30680606
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Blood Adv. 2022 Oct 25;6(20):5668-5675
pubmed: 35482455
Cancers (Basel). 2020 Dec 03;12(12):
pubmed: 33287347
J Thorac Dis. 2018 Feb;10(2):816-824
pubmed: 29607153
Prog Neurobiol. 2013 Feb-Mar;101-102:18-34
pubmed: 22743551
Cancer Inform. 2005;1:98-104
pubmed: 19305635
Proteomics. 2006 May;6(10):3189-98
pubmed: 16586434
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Clin Chem Lab Med. 2019 Aug 27;57(9):1388-1396
pubmed: 30860975
Cytokine. 2016 Aug;84:17-24
pubmed: 27208752
Proteome Sci. 2013 Mar 21;11(1):10
pubmed: 23518135
Front Neurol. 2015 Aug 19;6:179
pubmed: 26347708
Cancer Inform. 2005;1:86-97
pubmed: 19305634